definiens: shall mean, with respect to a Product, the gross amounts invoiced on sales of such Product byJanssen ( it being understood that, for purposes of this de ﬁnition, any such gross amounts invoiced by an Aﬃliate of Janssenor a Sublicensee shall be deemed to be invoiced by [COMPANY] ) t o a Third Party or Governmental Authority purchaser inarm’s - length transactions, less the following customary dedu ctions, determined in accordance with GAAP and standardinternal policies, procedures, and accounting standards consi stently applied throughout [COMPANY] to calculate revenue forﬁnancial reporting purposes, including deductions actually t aken, paid, accrued, allocated or allowed based on good faithestimates, with respect to such sales ( and consistently applied as set forth below):(a ) normal and customary trade, cash or quantity discounts, allo wances, wholesaler and pharmacy fees, andcredits allowed or paid, in the form of deductions actua lly allowed or actually paid with respect to sales of such Pr oduct ( tothe extent not already reflected in the amount invoiced ) excluding commissions for commercialization;(b ) excise taxes, use taxes, tariﬀs, sales taxes and customs duties, or other government charges imposed onthe sale of such Product ( including VAT, but only to the exte nt16that such VAT is not reimbursable or refundable ), but sp eciﬁcally excluding, for clarity, any income taxes assessed againstthe income arising from such sale ; ( c ) outbound freight, shipment and insurance costs to the exten t included in the price and separatelyitemized on the invoice;(d ) compulsory and negotiated payments and cash rebates imposed speciﬁcally in relation to sales of suchProduct ( rather than the turnover of a Party generally ) t o the extent the same are paid to a Governmental Author ity ( or agentthereof ) pursuant to governmental regulations by reason of any national or local health insurance program or sim ilarprogram that relate speciﬁcally to the Product, including pay - for - performance agreements or risk sharing agreements inrelation to such Product, but not including government le vied fees that are not speciﬁc to a Product such as those levie d asa result of the Patient Protection and Aﬀordable Care Act, Pub . L. No . 111 - 148 ( the ) or any other successorprogram ; ( e ) retroactive price reductions, credits or allowances actually granted upon rejections or returns of suchProduct, including for recalls or damaged good and billi ng errors;(f ) rebates, chargebacks, administrative fees, and discounts ( or e quivalent thereof ) to managed health careorganizations, group purchasing organizations, insurers, ph armacy beneﬁt managers ( or equivalent thereof ), specialtypharmacy providers, Governmental Authorities, or their age ncies or purchasers, reimbursers, or trade customers, as well asamounts owed to patients through co - pay assistance cards or si milar forms of rebate to the extent the latter are di rectlyrelated to the prescribing of the Product ; and(g ) [ * * * ]